<DOC>
	<DOCNO>NCT00969527</DOCNO>
	<brief_summary>The purpose study assess efficacy Oncoxin+Viusid administration treatment rheumatoid arthritis . The duration double-blind placebo control phase 3 clinical trial 12 week . The estimated number person rheumatoid arthritis recruit randomize study 86 . The primary outcome measure : DAS28 score assess end study .</brief_summary>
	<brief_title>Efficacy Oncoxin Plus Viusid Treatment Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Treatmentnaive subject recent onset rheumatoid arthritis Signed informed consent Subjects rheumatoid arthritis symptom associate joint disease onset Subjects joint function impairment secondary condition associate rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Oncoxin</keyword>
	<keyword>Viusid</keyword>
	<keyword>dietary supplement</keyword>
	<keyword>rheumatoid arthritis</keyword>
</DOC>